Advertisement

Therapeutic Strategies Employing CD4, the HIV Receptor

  • Per Ashorn
  • Bernard Moss
  • Edward A. Berger
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 312)

Abstract

Infection of T-lymphocytes and macrophages by human immunodeficiency virus (HIV) is initiated by binding of the external subunit of the viral envelope glycoprotein (gp120) to CD4 molecules on the target cell membrane (1). Recombinant soluble forms of CD4 retain the capacity for high affinity binding to gp120 (2, 3, 4, 5, 6, 7), suggesting potential therapeutic uses of CD4 derivatives. The diverse concepts for exploiting the CD4/gp120 interaction for therapy are outlined in Figure 1. The initial concept was based on the finding that soluble truncated forms of CD4 (sCD4) are able to neutralize HIV infectivity in vitro (2, 3, 4, 5, 6) (Figure 1A). Several “second generation” applications of this neutralizing concept are under development, including attachment of the CD4 to immunoglobulin constant region sequences (8, 9, 10, 11, 12), or presentation of the CD4 in association with erythrocytes (13). These modifications provide the advantages of increased plasma half-life compared to sCD4, and possibly enhanced efficiency of neutralization due to multivalency. Recent findings indicate that sCD4 is capable of “stripping” gp120 from the envelope glycoprotein complex (14, 15, 16), suggesting that the mechanism of sCD4 neutralization of HIV infectivity might involve more than simple competition for gp120 binding to CD4 on the surface of the target cell.

Keywords

Human Immunodeficiency Virus Human Immunodeficiency Virus Type Human Immunodeficiency Virus Infection Envelope Glycoprotein Human Immunodeficiency Virus Replication 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Klatzman, D.R., McDougal, J.S., Maddon, P.J., 1990, the CD4 Molecule and HIV infection, Immunodef. Rev. 2:43Google Scholar
  2. 2.
    Smith, D.H., Byrn, R.A., Marsters, S.A., Gregory, T., Groopman, J E, Capon, D.J., 1987, Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen, Science 238:1704.CrossRefPubMedGoogle Scholar
  3. 3.
    Fisher, R.A., Bertonis, J.M., Meier, W., Johnson, V.A., Costopoulos, D.S., Liu, T., Tizard, R., Walker, B.D.,Hirsch, M.S.,Schooley, R.T., Flavell, R.A., 1988, HIV infection is blocked in vitro by recombinant soluble CD4, Nature 331:76.CrossRefPubMedGoogle Scholar
  4. 4.
    Hussey, R.E., Richardson, N.E., Lowalski, M., Brown, N.R., Chang, H.-C., Siliciano, R.F., Dorfman, T., Walker, B., Sodroski, J., Reinherz, E.L., 1988, a soluble CD4 protein selectively inhibits HIV replication and syncytium formation, Nature 331:78.CrossRefPubMedGoogle Scholar
  5. 5.
    Deen, K.C., McDougal, J.S., Inacker, R., Folena-Wasserman, G., Arthos, J., Rosenberg, J., Maddon, P.J., Axel, R., Sweet, R.W., 1988, a soluble form of CD4 (T4) protein inhibits AIDS virus infection, Nature 331:82.CrossRefPubMedGoogle Scholar
  6. 6.
    Traunecker, A., Luke, W., Karjalainen, K., 1988, Soluble CD4 molecules neutralize human immunodeficiency type 1, Nature 331:84.CrossRefPubMedGoogle Scholar
  7. 7.
    Berger, E.A., Fuerst, T.R., Moss, B., 1988, a soluble recombinant polypeptide comprising the amino-terminal half of the extracellular region of the CD4 molecule contains an active binding site for human immunodeficiency virus, Proc. Natl. Acad. Sci., USA 85:2357.CrossRefGoogle Scholar
  8. 8.
    Capon, DJ., Chamow, S.M., Mordenti, J., Marsters, S.A., Gregory, T., Mitsuya, H., Byrn, R.A., Lucas, C., Wurm, F.M., Groopman, J.E., Smith, D.H., 1989, Designing CD4 immunoadhesions for AIDS therapy, Nature 337:525.CrossRefPubMedGoogle Scholar
  9. 9.
    Traunecker, A., Schneider, J., Kiefer, H., Karjalainen, K., 1989, Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules, Nature 339:68.CrossRefPubMedGoogle Scholar
  10. 10.
    Mizukami, T., Smith, C.D., Berger, E.A., Moss, B., 1989, Expression and characterization of chioneric proteins containing human CD4 linked to human immunoglobulin heavy chain constant regions, V. Int. Conf. AIDS Abst. M.C. p.89, p.556.Google Scholar
  11. 11.
    Byrn, R.A., Mordenti, J., Lucas, C., Smith, D., Marsters, S.A., Johnson, J.S., Cossum, P., Chamow, S.M., Wurm, F.M., Gregory, T., Groopman, J.E., Capon, D.J., 1990, Biological properties of a CD4 immunoadhesius, Nature 344:667.CrossRefPubMedGoogle Scholar
  12. 12.
    Zettlmeissl, G., Gregersen, J.P., Duport, J.M., Mehdi, S., Reiner, G., Seed, B., 1990, Expression and characterization of human CD4 immunoglobulin fusion proteins, DNA Cell. Biol. 9:347.Google Scholar
  13. 13.
    Mouneimne, Y., Tosi, P.F., Barhoumi, R., Nicolau, C., 1990, Electroinsertion of full length recombinant CD4 into red blood cell membrane, Biochim. Biophys. Acta 1027:53.Google Scholar
  14. 14.
    Kirsh, R., Hart, T.K., Ellens, H., Miller, J., Petteway, S.A., Lambert, D.M., Leary, J., Bugelski, P.J., 1990, Morphometric analysis or recombinant soluble CD4 mediated release of the envelope glycoprotein gp120 from HIV-1, AIDS Res. Hum. Retroviruses 6:1209.CrossRefGoogle Scholar
  15. 15.
    Moore, J.P., McKeating, J.A., Weiss, R.A., Sattentau, Q.J., 1990, Dissociation of gp120 from HIV-1 virions induced by soluble CD4, Science 250:1139.CrossRefPubMedGoogle Scholar
  16. 16.
    Berger, E.A., Lifson, J.D., Eiden, L.E., 1991, Stimulation of glycoprotein gp120 dissociation from the envelope glycoprotein complex of human immunodeficiency virus type 1 by soluble CD4 and CD4 peptide derivatives: implications for the role of the complementarity - dtermining region 3-like region in membrane fusion, Proc. Natl. Acad. Sci USA 88:8082.CrossRefPubMedGoogle Scholar
  17. 17.
    Chaudhary, V.K., Mizukami, T., Fuerst, T.R., FitzGerald, D.J., Moss, B., Pastan, I., Berger, E.A., 1988, Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein, Nature 333:369.CrossRefGoogle Scholar
  18. 18.
    Till, M.A., Ghetie, V., Gregory, T., Patzer, E.J., Porter, J.P., Uhr, J.W., Capon, DJ., Vitetta, E.S., 1988, HIV-infected cells are killed by rCD4-ricin A chain, Science 242:1166.CrossRefPubMedGoogle Scholar
  19. 19.
    Zverev, V., Malushova, V., Sidorov, A., Zdanovsky, A., Blinov, V., Korneeva, M., Pugach, A., Yankovsky, N., Andjaparidze, O., 1990, Inhibition of the infectivity of HIV by different recombinant forms of CD4, VI Int. Conf. AIDS Abst. th. A. 252, vo1 1, p. 183.Google Scholar
  20. 20.
    Cudd, A., Noonan, C.A., Tosi, P.F., Melnick, J.L., Nicolau, C., 1990, Specific interaction of CD4-bearing liposomes with HIV-infected cells, J. Acquir. Immune Defic. Syndr. 3:109.PubMedGoogle Scholar
  21. 21.
    Lever, A., Richardson, J., Gottlinger, H., Haseltine, W.A., Sodroski, J., 1990, Development of a retroviral vector system based on HIV, VI Int. Conf. AIDS Abst. S.A. 349, vol. 3, p. 169.Google Scholar
  22. 22.
    Agrawal, S., Ikeuchi T., Sun, D., Sarin, S., Konopka, A., Maizel, J., Zamecnik, P.C., 1990, Inhibition of human immunodeficiency virus in early infected and chronically infected cells by antisense oligodeoxynucleotides and their phosphorothioate analogues, Proc. Natl. Acad. Sci., USA 86:7790.CrossRefGoogle Scholar
  23. 23.
    Sarver, N., Cantin, E.M., Chang, P.S., Zaia, J.A., Ladne, P.A., Stephens, D.A., Rossi, J.J., 1990, Ribozymes as potential anti-HIV-1 therapeutic agents, Science 247:1222.CrossRefPubMedGoogle Scholar
  24. 24.
    Pastan, I., FitzGerald, D., 1989, Pseudomonas exotoxin: Chimeric Toxins, J. Biol. Chem. 264:15157.PubMedGoogle Scholar
  25. 25.
    Berger, E.A., Clouse, K.A., Chaudhary, V.K., Chakrabarti, S., FitzGerald, D.J., Pastan, I., Moss, B., 1989, CD4-Pseudomonas exotoxin hybrid protein blocks the spread of human immunodeficiency virus infection in vitro and is active against cells expressing the envelope glycoproteins from diverse primate immunodeficiency retroviruses, Proc. Natl. Acad. Sci. USA 86:9539.CrossRefPubMedGoogle Scholar
  26. 26.
    Berger, E.A., Chaudhary, V.K., Clouse, K.A., Jaraquemada, D., Nicholas, J.A., Rubino, K.L., FitzGerald, DJ., Pastan, I., Moss, B., 1990, Recombinant CD4Pseudomonas exotoxin hybrid protein displays HIV-specific cytotoxicity without affecting MHC-class II-dependent functions, AIDS Res. Hum. Retroviruses 6:795.CrossRefPubMedGoogle Scholar
  27. 27.
    Ashorn, P., Moss, B., Weinstein, J.N., Chaudhary, V.K., FitzGerald, D.J., Pastan, I., Berger, E.A., 1990, Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors, Proc. Natl. Acad. Sci. USA 87:8889.CrossRefPubMedGoogle Scholar
  28. 28.
    Ashorn, P, Englund, G., Martin, M.A., Moss, B., Berger, E.A., 1991, Anti-HIV activity of CD4-Pseudomonas exotoxin on infected primary human lymphocytes and monocyte/macrophages, J. Infect. Dis., 163:703.CrossRefPubMedGoogle Scholar
  29. 29.
    Rosenberg, Z.F., Fauci, A.S., 1990, Immunopathogenic mechanisms of HIV infection: Cytokine induction of HIV expression, Immunology Today 11:176.CrossRefPubMedGoogle Scholar
  30. 30.
    Johnson, V.A., Hirsh, M.S., 1989, Antiviral Chemotherapy: New directions for clinical applications and research, J. Mills and L. Corey, eds., Elsevier, New York, 2:275.Google Scholar
  31. 31.
    Yarchoan, R., Mitsuya, H., Myers, C.E., Broder, S., 1989, Clinical pharmacology of 3’-azido 2’, 3’-dideoxythymidine (zidovudine) and related dideoxynucleosides, N. Engl. J. Med. 321:726.CrossRefPubMedGoogle Scholar
  32. 32.
    Daar, E.S., Li, X.L., Moudgil, T., Ho, D.D., 1990, High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates, Proc. Natl. Acad. Sci., USA 87:6574.CrossRefPubMedGoogle Scholar
  33. 33.
    Callahan, L.N., Norcross, M.A., 1989, Inhibition of soluble CD4 therapy by antibodies to HIV (letter), Lancet 734.Google Scholar
  34. 34.
    Loberboum-Galski, H., Barrett, L.V., Kirkman, R.L., Ogata, M., Willingham, M.C., FitzGerald, D.J., Pastan, I., 1989, Cardiac allograft survival in mice treated with IL2–PE40, Proc. Natl. Acad. Sci. USA 86:1008.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1992

Authors and Affiliations

  • Per Ashorn
    • 1
  • Bernard Moss
    • 1
  • Edward A. Berger
    • 1
  1. 1.Laboratory of Viral DiseasesNational Institute of Allergy and Infectious Diseases National Institutes of HealthBethesdaUSA

Personalised recommendations